vociprotafib + adagrasib

vociprotafib + adagrasib is a combination of two small molecule drugs, each clinically investigated as a targeted therapy for cancers harboring specific genetic mutations. - Adagrasib is an orally administered, covalent small molecule inhibitor that irreversibly binds and inhibits the KRAS G12C mutant protein, thereby blocking its contribution to oncogenic signaling pathways (MAPK/ERK and PI3K/AKT) and halting tumor growth[1][2][3][5]. - Adagrasib is FDA-approved for use (often as "Krazati") in KRAS G12C-mutated non-small cell lung cancer (NSCLC) and, in combination with cetuximab, for KRAS G12C-mutated metastatic colorectal cancer (CRC)[5]. - Vociprotafib appears to be a code name suggesting a new, investigational agent, but no substantial clinical data, mechanism, or indication for vociprotafib can be found in the provided search results or current literature. - If vociprotafib is used in combination with adagrasib, it is likely the result of ongoing research aimed at expanding targeted therapy for solid tumors, but no clinical trial, approval status, or precise mechanism is currently documented for the combination. - The combination of adagrasib (and similar KRAS G12C inhibitors) with other drugs aims to overcome resistance and improve efficacy in refractory KRAS G12C-mutated cancers.

Other names

vociprotafibadagrasibKrazati